RxDoctor Payments Data

Syed Karim, MD

Ophthalmology · Sellersville, PANPI 1457771537

Payments from drug & device makers

$1,648in general payments, 2019–2025

Across 54 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$397
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$212
  • Bausch & Lomb Americas Inc.$207
  • Sun Pharmaceutical Industries Inc.$126
  • Johnson & Johnson Surgical Vision, Inc.$113
  • Glaukos Corporation$102
  • plus $490 from 13 others

What the payments were for

  • Food & beverage$1,62899%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,648 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$432,136
Medicare patients
789
Services billed
2,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine38$26,748
RestasisCyclosporine21$25,507
LumiganBimatoprost45$17,357
Prednisolone Acetate295$9,074
DurezolDifluprednate11$6,066
Loteprednol Etabonate29$3,742
Latanoprost283$3,008
Difluprednate21$2,097
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat98$1,522
ErythromycinErythromycin Base85$957
Dorzolamide Hcl47$893
Timolol Maleate83$761
Ofloxacin72$738
Brimonidine Tartrate89$675
Acyclovir24$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$31$42,86466 claims
NovartisDurezol$91$6,06611 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$212$3,74229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Sellersville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →